Adaptive Biotechnologies Corp (NASDAQ:ADPT) Q2 2020 Earnings Conference Call - Final Transcript
Aug 10, 2020 • 04:30 pm ET
Ladies and gentlemen, thank you for standing by, and welcome to the Adaptive Biotechnologies Second Quarter Financial Results Conference Call. [Operator instructions]
I would now like to hand the call over to your speaker today, Ms. Karina Calzadilla. Please go ahead.
Thank you, Keno, and good afternoon, everyone. I would like to welcome you to Adaptive Biotechnologies second quarter 2020 earnings conference call. Earlier today, we issued a press release reporting Adaptive's financial results for the second quarter of 2020. The press release is available on our corporate website at www.adaptivebiotech.com. We are conducting a live webcast of this call, a replay of which will be available on our website after its conclusion.
I would also like to remind you that during the call, management will make projections and other forward-looking statements within the meaning of federal securities laws regarding future events and the future financial performance of the company. It is important to note that these statements reflect management's current perspective of the business as of today's date.
Actual results may differ materially from current expectations and projections depending on a number of factors, which are set forth in our public filings with the Securities and Exchange Commission, including the Form 10-Q to be filed today.Adaptive disclaims any intent or obligation to update these forward-looking statements except as expressly required by law.
In addition, non-GAAP financial measures will be discussed during the call. Our GAAP financial metrics and reconciliation from non-GAAP to GAAP metrics can be found in our earnings release issued earlier. Joining the call today are Chad Robins, our CEO and co-founder; Julie Rubinstein, our president; and Chad Cohen, our chief financial officer. In addition, Harlan Robins, Adaptive's chief scientific officer and co-founder will be available for Q&A.
With that, I will turn the call over to Chad Robins. Chad?
Thanks, Karina, and good afternoon, everybody, and thank you for joining us on our second quarter 2020 earnings call. I hope that you and your loved ones are staying safe and healthy as we continue to navigate through these difficult times. I want to start off by saying, I'm truly honored to be part of the Adaptive team, and want to congratulate my colleagues on our first year anniversary from our IPO. The past months have been challenging for everyone, and our entire company has shown unwavering dedication and flexibility.
Thank you to all our Adaptive employees. As you all know, the current coronavirus pandemic is highlighting the critical importance of understanding immune response to disease broadly, making Adaptive's technology more relevant than ever. At Adaptive, we're focused on translating the genetics of the adaptive immune system into clinical products to detect and treat disease, and we are committed to leveraging our immune medicine platform to support the efforts to combat COVID-19 pandemic. COVID-19 brought the role of the immune system to the forefront of society and has created the opportunity for Adaptive to be positioned as the go-to company to rapidly and reproducibly assess the T cell